Sr. Principal Scientist Drug Product Development
BMS
Plainsboro, New Jersey
Hiten is a senior principal scientist in biologics drug product development at Bristol-Myers Squibb (BMS). Hiten has coedited the book "Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (Springer)", a 2018 anthology that explores the complexity of biosimilars regulation in key geographies.
Before joining BMS, Hiten was associate director of formulation development at Outlook Therapeutics, where he developed a proprietary bevacizumab product for intravitreal injection. He worked on stabilization of novel insulin analogs at Thermalin Diabetes. He worked at Biocon, USV, and Reliance Biopharmaceuticals in India in pharmaceutical development of biosimilar insulins and hormones.
Hiten earned his doctorate in pharmacognosy (pharmaceutical biotechnology track) from the University of Illinois at Chicago, College of Pharmacy. His research involved structural and functional characterization of fructose 1,6-bisphosphatase from Mycobacterium tuberculosis and Francisella tularensis. During the program, Hiten did a co-op in MedImmune’s formulation development group. He earned his bachelor’s degree in pharmaceutical sciences from the University of Mumbai, India, and his master’s in pharmaceutical sciences from the University Institute of Chemical Technology, also in Mumbai.
Hiten is a current member of the American Association of Pharmaceutical Sciences (AAPS) and serves on the editorial board of the Taylor & Francis journal mAbs and the magazine Bioprocess International.
Disclosure information not submitted.
Monday, October 17, 2022
3:00 PM – 4:00 PM ET